ODTX (ODTX) Stock Price & Analysis
ODTX (ODTX) fell 0.18% to USD 17.09 as of June 10, 2026 at 09:58 UTC, according to Nexqual real-time market data.
ODTX last closed at USD 17.12; the session ranged USD 16.93–17.55 on volume of 268,844 shares. Market capitalization is $806.21M, with a 52-week range of USD 15.35–20.3 (NCM). Source: Nexqual, June 10, 2026 at 09:58 UTC.
Key Statistics (as of June 10, 2026 at 09:58 UTC)
| Price | USD 17.09 |
|---|---|
| Change | ▼ 0.18% (down) |
| Previous Close | USD 17.12 |
| Open | USD 17.25 |
| Day Range | USD 16.93 – 17.55 |
| 52-Week Range | USD 15.35 – 20.3 |
| Volume | 268,844 shares |
| Market Cap | $806.21M |
| Exchange | NCM |
Technical Analysis (ODTX)
Nexqual's technical model rates ODTX "SELL" based on 0 bullish and 2 bearish signals across 21 daily candles, as of June 10, 2026 at 09:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 54.86 (neutral) |
Analyst Ratings (ODTX)
Wall Street analysts rate ODTX "Strong Buy" based on 3 analysts, with a mean price target of USD 32 (range USD 26–40), per Nexqual as of June 10, 2026 at 09:58 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 32 |
| High Target | USD 40 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (ODTX)
| EPS Estimate | USD -1.28 |
|---|---|
| Revenue Estimate | $0 |
Source: Nexqual, June 10, 2026 at 09:58 UTC.
Financials & Fundamentals (ODTX)
| Total Revenue | $2.98M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -10739.72% |
| Profit Margin | +0.00% |
| ROE | -85.50% |
| Debt / Equity | 15.24 |
| Current Ratio | 7.2 |
| Total Cash | $187.00M |
| Total Debt | $34.38M |
| Free Cash Flow | $-85.05M |
Source: Nexqual, June 10, 2026 at 09:58 UTC.
Financial Health Score (ODTX)
Nexqual rates ODTX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $187M cash vs $34M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$129M |
| Efficiency | Critical — ROE -86%, ROA -41.7% |
Ownership (ODTX)
| Insider Ownership | +1.97% |
|---|---|
| Institutional Ownership | +48.11% |
| Shares Outstanding | 47.17M |
| Float | 11.59M |
| Short % of Float | +1.25% |
Source: Nexqual, June 10, 2026 at 09:58 UTC.
Leadership (ODTX)
ODTX is led by Gary D. Glick (age 63), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 09:58 UTC.
| Founder, President, CEO & Director | Gary D. Glick (age 63) |
|---|---|
| Chief Financial Officer | Jason Haas (age 57) |
| Senior Vice President of Strategy & Business Development | Collin Todd (age 33) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, In | USD 27 | ▲ 6.72% |
| SPTX | Seaport Therapeutics, Inc. | USD 17.66 | ▲ 7.42% |
| AVLN | Avalyn Pharma Inc. | USD 28.67 | ▲ 5.95% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:58 UTC. This page is informational and not investment advice.